Corticosteroid pulse combination therapy for refractory Kawasaki disease: A randomized trial

Pediatrics

Volumn 129, Issue 1, 2012, Pages

  Ogata, Shohei ^a   Ogihara, Yoshihito ^a   Honda, Takashi ^a   Kon, Shinya ^a   Akiyama, Kazumasa ^a   Ishii, Masahiro ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Intravenous immunoglobulin; Kawasaki disease; Methylpredonine pulse; Prediction score; Resistant patient

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; C REACTIVE PROTEIN; HEPARIN; IMMUNOGLOBULIN; METHYLPREDNISOLONE;

AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BRADYCARDIA; CHILD; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EGAMI SCORE; FEMALE; FEVER; HUMAN; HYPERTENSION; HYPOTHERMIA; INFANT; JAPAN; MAJOR CLINICAL STUDY; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; THROMBOCYTE COUNT;

EID: 84855269257     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2011-0148     Document Type: Article

References (26)

1. Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974;54(3):271-276
2. Newburger JW, Takahashi M, Gerber MA, et al. Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004;114(6):1708-1733 (Pubitemid 41754943)
3. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP; US/Canadian Kawasaki Syndrome Study Group. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. Pediatr Infect Dis J. 1998;17(12):1144-1148 (Pubitemid 29023891)
4. Tremoulet AH, Best BM, Song S, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr. 2008;153(1):117-121
5. Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr. 2006;149(2):237-240 (Pubitemid 44128552)
6. Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006;113(22):2606-2612 (Pubitemid 43948009)
7. Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr. 2007;166(2):131-137 (Pubitemid 46025504)
8. Ogata S, Bando Y, Kimura S, et al. The strategy of immune globulin resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. J Cardiol. 2009;53(1):15-19
9. Hashino K, Ishii M, Iemura M, Akagi T, Kato H. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int. 2001;43(3):211-217 (Pubitemid 32640933)
10. Wright DA, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr. 1996;128(1):146-149 (Pubitemid 26028974)
11. Okada K, Hara J, Maki I, et al. Osaka Kawasaki Disease Study Group. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. Eur J Pediatr. 2009;168(2):181-185
12. Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child. 2008;93(2):142-146 (Pubitemid 351204755)
13. Miura M, Kohno K, Ohki H, Yoshiba S, Sugaya A, Satoh M. Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. Eur J Pediatr. 2008;167(10):1119- 1123
14. Sundel RP, Baker AL, Fulton DR, Newburger JW. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr. 2003;142(6):611-616 (Pubitemid 36737160)
15. Ogata S, Ogihara Y, Nomoto K, et al. Clinical score and transcript abundance patterns identify Kawasaki disease patients who may benefit from addition of methylprednisolone. Pediatr Res. 2009;66(5):577-584
16. Newburger JW, Sleeper LA, McCrindle BW, et al. Pediatric Heart Network Investigators. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med. 2007;356(7):663-675
17. Ayusawa M, Sonobe T, Uemura S, et al. Kawasaki Disease Research Committee. Revision of diagnostic guidelines for Kawasaki disease. 5th revised ed. Pediatr Int. 2005;47(2):232-234 (Pubitemid 40545436)
18. de Zorzi A, Colan SD, Gauvreau K, Baker AL, Sundel RP, Newburger JW. Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr. 1998;133(2):254-258
19. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics. 1979;63(2):175-179 (Pubitemid 9083134)
20. Niwa Y, Sohmiya K. Enhanced neutrophilic functions in mucocutaneous lymph node syndrome, with special reference to the possible role of increased oxygen intermediate generation in the pathogenesis of coronary thromboarteritis. J Pediatr. 1984;104(1):56-60 (Pubitemid 14178461)
21. Takahashi K, Oharaseki T, Naoe S, Wakayama M, Yokouchi Y. Neutrophilic involvement in the damage to coronary arteries in acute stage of Kawasaki disease. Pediatr Int. 2005;47(3):305-310 (Pubitemid 40827508)
22. Abe J, Ebata R, Jibiki T, Yasukawa K, Saito H, Terai M. Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease. J Allergy Clin Immunol. 2008;122(5):1008-1013. e8.
23. Clynes R. IVIG therapy: interfering with interferon-gamma. Immunity. 2007;26(1):4-6
24. Gill V, Doig C, Knight D, Love E, Kubes P. Targeting adhesion molecules as a potential mechanism of action for intravenous immunoglobulin. Circulation. 2005;112(13):2031-2039 (Pubitemid 41377423)
25. Terai M, Honda T, Yasukawa K, Higashi K, Hamada H, Kohno Y. Prognostic impact of vascular leakage in acute Kawasaki disease. Circulation. 2003;108(3):325-330 (Pubitemid 36899024)
26. Sleeper LA, Minich LL, McCrindle BM, et al. Pediatric Heart Network Investigators. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr. 2011;158(5):831-835.e3